新型抗真菌药物——olorofim

A novel antifungal drug:olorofim

olorofim(研发代号:F901318)是一款由F2G公司开发的新型抗真菌药物,主要用于治疗严重侵袭性真菌感染。olorofim与现有的抗真菌药物具有不同的作用机制,通过抑制二氢乳清酸脱氢酶(DHODH)破坏嘧啶的生物合成,从而干扰正常细胞功能,并最终发挥抗真菌活性。此外,olorofim能够选择性地靶向抑制真菌DHODH,对人体具有安全性。olorofim获得欧洲药品管理局与FDA授予的多项突破性疗法及孤儿药称号,是首个被授予突破性疗法称号的抗真菌药物,有望解决侵袭性曲霉病和其他罕见霉菌疾病治疗药物资源不足的现状。本文就olorofim的基本信息、作用机制、临床前研究及临床研究等进行概述。

Olorofim(research code:F901318)is a novel antifungal drug developed by F2G Ltd.,primarily designed for the treatment of severe invasive fungal infections.Olorofim has a different mechanism compared to existing antifungal agents.It exerts its antifungal activity by inhibiting dihydroorotate dehydrogenase(DHODH),thereby disrupting pyrimidine biosynthesis and interfering with normal cell function.In addition,olorofim can selectively target the fungal DHODH,which has an ideal safety profile in humans.Olorofim has been awarded multiple breakthrough therapy and orphan drug designations by both the EMA and the FDA.It is the first antifungal drug to receive breakthrough therapy designation,and it is expected to address unmet medical needs caused by invasive aspergillosis and other rare fungal diseases.This article provides an overview of oloro⁃fim's basic information,mechanism,preclinical and clinical studies.